Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Multicenter, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Mild to Moderate Alzheimer's Disease. Revised Protocol 04, incorporating Administrative Letters 01 & 02, Protocol Amendment 02 (v1.0, dated 02-Feb-2009), Amendment 03 (v1.0, dated 27-Mar-2009), Amendment 04 (v1.0, dated 03-Sep-2009) and Amendment 05 (v1.0, dated 18-Feb-2010). And Pharmacogenetics Blood Sample Amendment 01 - Site Specific (v1.0, dated 14-Nov-2008)
To assess the safety and tolerability of BMS-708163 in patients with mild to moderate Alzheimer’s disease.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery. Revised Protocol 01, incorporating Protocol Amendment 02 (Version 3.0, date 22-July-2007). And Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 3.0, dated 14-Aug-06
The primary objective is to compare the effect of oral (PO) apixaban 2.5 mg BID versus subcutaneous (SC) enoxaparin 30 mg q12h on the composite endpoint of adjudicated asymptomatic and symptomatic DVT...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Comparative Study of Entecavir vs Adefovir vs the Combination in Lamivudine- Refractory Chronic Hepatitis B Subjects The DEFINE Study Revised Protocol 01
To compare the proportion of subjects in the combination therapy group to the proportion of subjects in each of the monotherapy treatment groups who achieve HBV DNA lt; 50 IU/mL approximately 300 co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A study to assess the efficacy and safety of Nivolumab and Ipilimumab in the treatment of patients with Stage III or IV Melanoma. Patients will then receive Nivolumab until the end of the study
The primary objective of this study is to determine the incidence of high-grade (CTCAE v4.0 Grades 3-5), treatment-related, select adverse events of potentially immune-mediated etiology (pulmonary, ga...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase IIIB, Multi-Center, Randomized, Double Blind, Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept Plus Methotrexate Compared with Methotrexate. Revised Protocol 04, incorporating Protocol Amendments 05, 06, 08, 09 (V1.0 dated 18-Nov-2008) and Administrative Letter 02. Pharmacogenetics Amendment 1 dated 16-May-2005. Protocol Amendments 3 & 4 - Site Specific - dated 28-Dec-2005. And Protocol Amendment 07 - Site Specific (v2.0, date 27-Jul-2007)
The co-primary objectives for this study will compare the clinical efficacy of abatacept used in combination with methotrexate versus methotrexate alone on the following: 1) The proportion of subjects...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Safety and Efficacy Study of Daclatasvir 60mg, Sofosbuvir 400mg, and Ribavarin (dosed based upon weight) in subjects with chronic Genotype 3 Hepatitis C infection with or without prior treatment experience and compensated advanced cirrhosis for 12 or 16 weeks
The purpose of this study is to determine if the use of Daclatasvir, Sofosbuvir, and Ribavarin in combination is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patient...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjects. Revised Protocol 02 incorporating amendment 03 (Version 1.0, Date 09-Mar-2007) and amendment 04 (Version 1.0, Date 02-Jul-2007). And Pharmacogenetics Blood Sample Amendment 01 - Site Specific (Version 5.0, Date 14-Sep-2006)
To assess the effect of multiple-dose FAM BID on the multiple-dose PK of ATV/RTV in HIV-infected subjects when FAM is administered simultaneously (without TDF) or temporally separated (with TDF).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
The primary objective for this study is to demonstrate that subcutaneous (SC) injections of abatacept are non-inferior to intravenous (IV) infusions of abatacept in ACR 20 responses after 6 months of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers in Subjects Who Are Receiving Low Dose Acetylsalicylic Acid (ASA)
To assess if the withdrawal of clopidogrel 12 months after DES implantation leads to an increase in the level of soluble CD40 Ligand over a four weeks follow-up period.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 2 Relapsed or Refractory Multiple Myeloma trial - with or without Elotuzumab. Studio di fase 2 sul mieloma multiplo refrattario o recidivante - con o senza Elotuzumab
To compare Progression Free Survival between treatment arms in the overall population. Confrontare la Sopravvivenza Libera da Progressione tra i bracci di trattamento nella popolazione generale...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant